MED (Medifast) Cash And Cash Equivalents : $115.3 Mil (As of Sep. 2024)

View and export this data going back to 1981. Start your Free Trial

What is Medifast Cash And Cash Equivalents?

Medifast's quarterly cash and cash equivalents increased from Mar. 2024 ($97.47 Mil) to Jun. 2024 ($108.02 Mil) and increased from Jun. 2024 ($108.02 Mil) to Sep. 2024 ($115.31 Mil).

Medifast's annual cash and cash equivalents declined from Dec. 2021 ($104.18 Mil) to Dec. 2022 ($87.69 Mil) but then increased from Dec. 2022 ($87.69 Mil) to Dec. 2023 ($94.44 Mil).

Medifast Cash And Cash Equivalents Historical Data

The historical data trend for Medifast's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast Cash And Cash Equivalents Chart

Medifast Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

76.97

163.72

104.18

87.69

94.44

Medifast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															112.75	94.44	97.47	108.02	115.31

Medifast Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Medifast (NYSE:MED) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Medifast Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Medifast's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Medifast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0K05:UK MDF:Germany MDF:Germany

Address

100 International Drive, Baltimore, MD, USA, 21202

Website

https://www.medifastinc.com

Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.

Executives

Scott Schlackman	director	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Jeffrey J Brown	director	19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas	director	C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer	director	MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Hallquist Constance J.	director	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary	director	C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard	director, officer: Chief Executive Officer	NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie	officer: VP, Finance & CAO	100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney	officer: Chief Financial Officer	415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian	director	MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman	officer: (Interim) CFO	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson	officer: Chief Financial Officer	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117